Swiss Noema Pharma raises CHF54m in Series...Noema Pharma AG kicks off with CHF54m and licenced drug candidates from Roche AG. more ➔
Germany first EU country to launch COVID-1...After months of lobbying by the BIOM biotech cluster, Bavaria is launching a €50m initiative to push the best and fastest COVID-19 therapies. more ➔
Moderna to file for EU approval of mRNA-12...COVID-19 mRNA vaccine developer Moderna Inc reported it will file for FDA and EMA authorisation of mRNA-1273 based on Phase III results. more ➔
Drug set to rescue COVID-19 patients at IC...Aviptadil, a vasodilator originally developed to treat erectile dysfunction, led to a 72% survival in critically-ill COVID-19 patients. more ➔
Rapid antibody development to cure COVID-1...In addition to vaccination programmes, the SARS-CoV-2 pandemic requires safe and efficient treatment options for patients infected and suffering from Covid-19 disease. Virus-neutralising antibody therapeutics … more ➔
Polyphor AG bags funding for murepavadinPolyphor has secured $3.3m from the Cystic Fibrosis Foundation as support for clinical Phase I/IIa testing of its inhaled antibiotic murepavadin. more ➔
Searching for an effective treatment for C...Apogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is being evaluated in two clinical phase II trials in patients with COVID-19 disease. With its … more ➔
Global bioeconomy in the spotlight12 interactive workshops, five plenary sessions and more than 3,000 registered attendees – last week the Global Bioeconomy Summit brought together international experts to discuss major trends and d … more ➔
A pioneering real AI drug discovery techno...The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and … more ➔
Collaborating to accelerate vaccine manufa...Development of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate … more ➔
